Research ArticleBasic Sciences
Metabolic Trapping as a Principle of Radiopharmaceutical Design: Some Factors Responsible for the Biodistribution of [18F] 2-Deoxy-2-Fluoro-D-Glucose
Brian M. Gallagher, Joanna S. Fowler, Neal I. Gutterson, Robert R. MacGregor, Chung-Nan Wan and Alfred P. Wolf
Journal of Nuclear Medicine October 1978, 19 (10) 1154-1161;
Brian M. Gallagher
Joanna S. Fowler
Neal I. Gutterson
Robert R. MacGregor
Chung-Nan Wan
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Metabolic Trapping as a Principle of Radiopharmaceutical Design: Some Factors Responsible for the Biodistribution of [18F] 2-Deoxy-2-Fluoro-D-Glucose
Brian M. Gallagher, Joanna S. Fowler, Neal I. Gutterson, Robert R. MacGregor, Chung-Nan Wan, Alfred P. Wolf
Journal of Nuclear Medicine Oct 1978, 19 (10) 1154-1161;
Metabolic Trapping as a Principle of Radiopharmaceutical Design: Some Factors Responsible for the Biodistribution of [18F] 2-Deoxy-2-Fluoro-D-Glucose
Brian M. Gallagher, Joanna S. Fowler, Neal I. Gutterson, Robert R. MacGregor, Chung-Nan Wan, Alfred P. Wolf
Journal of Nuclear Medicine Oct 1978, 19 (10) 1154-1161;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?
- Can FDG-PET/CT imaging be used to predict decline in quality of life in interstitial lung disease? A prospective study of the relationship between FDG uptake and quality of life in a UK outpatient setting
- Organ-Specific Fuel Rewiring in Acute and Chronic Hypoxia Redistributes Glucose and Fatty Acid Metabolism
- Gallaghers Principle of Metabolic Trapping (perspective on "Metabolic Trapping as a Principle of Radiopharmaceutical Design: Some Factors Responsible for Biodistribution of [18F]2-Deoxy-2-Fluoro-D-Glucose" J Nucl Med. 1978;19:1154-1161)
- Assessing the Effect of Various Blood Glucose Levels on 18F-FDG Activity in the Brain, Liver, and Blood Pool
- PET/CT in nononcological lung diseases: current applications and future perspectives
- Elevated 18F-FDG Levels in Blood and Organs After Angiotensin II Receptor Blocker Administration: Experiment in Mice Administered Telmisartan
- Targeted Cancer Therapy with a 2-Deoxyglucose-Based Adriamycin Complex
- Is Liver SUV Stable over Time in 18F-FDG PET Imaging?
- Could Different Hydration Protocols Affect the Quality of 18F-FDG PET/CT Images?
- Role of Functional Imaging in the Management of Lymphoma
- Impact of 18F-FDG PET/CT with Retrograde Filling of the Urinary Bladder in Patients with Suspected Pelvic Malignancies
- Design of Targeted Cardiovascular Molecular Imaging Probes
- Modern Staging and Utility of PET Imaging in Esophageal Cancer Management
- Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study
- Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death
- Dynamic Small-Animal PET Imaging of Tumor Proliferation with 3'-Deoxy-3'-18F-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas
- 18F-FDG PET/CT Delayed Images After Diuretic for Restaging Invasive Bladder Cancer
- Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis
- Positherapy: Targeted Nuclear Therapy of Breast Cancer with 18F-2-Deoxy-2-Fluoro-D-Glucose
- Analysis of the Regional Uptake of Radiolabeled Deoxyglucose Analogs in Human Tumor Xenografts
- Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma
- Enhancing Targeted Radiotherapy by Copper(II)diacetyl- bis(N4-methylthiosemicarbazone) Using 2-Deoxy-D-Glucose
- 3'-Deoxy-3'-[18F]Fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography
- Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer
- 18F-FDG Accumulation with PET for Differentiation Between Benign and Malignant Lesions in the Thorax
- Metabolic Fate of 18F-FDG in Mice Bearing Either SCCVII Squamous Cell Carcinoma or C3H Mammary Carcinoma
- FDG Uptake and Glucose Transporter Subtype Expressions in Experimental Tumor and Inflammation Models
- Dual Time Point 18F-FDG PET Imaging for Differentiating Malignant from Inflammatory Processes
- Cellular Release of [18F]2-Fluoro-2-deoxyglucose as a Function of the Glucose-6-phosphatase Enzyme System
- Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
- Whole-Body Positron Emission Tomography Using 18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin's Disease and Non-Hodgkin's Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
- Current role of positron emission tomography in thoracic oncology
- Prediction of Improvement of Contractile Function in Patients With Ischemic Ventricular Dysfunction After Revascularization by Fluorine-18 Fluorodeoxyglucose Single-Photon Emission Computed Tomography
- Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects
- Positron emission tomography: human brain function and biochemistry
- Metabolic mapping of the brain's response to visual stimulation: studies in humans
- Cellular Release of [18F]2-Fluoro-2-deoxyglucose as a Function of the Glucose-6-phosphatase Enzyme System